Juxtapid

Drug - Juxtapid [Aegerion Pharmaceuticals, Inc.]

June 2013

Therapeutic area - Cardiovascular

Approval criteria

• Patient is greater than 18 years of age AND
• Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
• Baseline liver function tests have been completed AND
• Patient has tried and failed or is not a candidate for LDL-apheresis AND
• Female patients have had a pregnancy test and a confirmed negative result

Quantity limit

• 5 mg = 34
• 10 mg = 34
• 20 mg = 102

Background information

JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411